Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 53%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated a strong financial trajectory, with management projecting an increase in global sales for its Neuroscience segment to approximately $10.7 billion for 2025, reflecting a solid upward revision driven by contributions from Vyalev, Vraylar, the oral CGRP franchise, and Botox Therapeutic. The company has also raised its fiscal year 2025 earnings per share (EPS) guidance to a range of $12.09-$12.29, representing a positive midpoint adjustment, alongside a revenue guidance increase of $700 million to nearly $59.7 billion. Overall, AbbVie's impressive first quarter of 2025, characterized by robust sales of $13.34 billion and strong performances in its immunology, oncology, and neuroscience franchises, further substantiates a favorable outlook for the company.

Bears say

AbbVie faces significant downside risks that negatively impact its stock outlook, including disappointing commercial execution on key products such as Skyrizi, Rinvoq, and Botox, alongside potential regulatory setbacks affecting their clinical pipeline. The impending erosion of Humira's market share due to the entry of biosimilars, coupled with competitive pressures on its oncology products like Imbruvica, further complicates long-term growth expectations. Additionally, macroeconomic challenges, particularly in the Aesthetics segment and broader industry dynamics, threaten to undermine expected revenues and earnings, with increased costs in SG&A and R&D exacerbating financial outcomes.

AbbVie (ABBV) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 53% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 15 analysts, AbbVie (ABBV) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $248.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $248.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.